[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Curis Inc (CRIS)

Curis Inc (CRIS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,618
  • Shares Outstanding, K 1,949
  • Annual Sales, $ 9,440 K
  • Annual Income, $ -7,580 K
  • EBIT $ -33 M
  • EBITDA $ -33 M
  • 60-Month Beta 3.08
  • Price/Sales 1.09
  • Price/Cash Flow N/A
  • Price/Book 0.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-5.80
  • Number of Estimates 1
  • High Estimate $-5.80
  • Low Estimate $-5.80
  • Prior Year $-13.60
  • Growth Rate Est. (year over year) +57.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.61 +37.32%
on 06/25/26
11.40 -56.49%
on 06/30/26
-3.98 (-44.53%)
since 06/09/26
3-Month
3.61 +37.32%
on 06/25/26
15.80 -68.61%
on 04/15/26
-5.24 (-51.37%)
since 04/09/26
52-Week
3.61 +37.32%
on 06/25/26
40.28 -87.69%
on 07/11/25
-31.64 (-86.45%)
since 07/09/25

Most Recent Stories

More News
Curis Consents First Six Patients in TakeAim CLL Study

LEXINGTON, Mass. , July 6, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...

CRIS : 4.96 (+0.51%)
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split

Eleven sites open for patient enrollment in TakeAim CLL combination study with zanubrutinib; Company reaffirms guidance for dosing of initial five patients by end of July 2026 with data expected December...

CRIS : 4.96 (+0.51%)
Curis: Q1 Earnings Snapshot

Curis: Q1 Earnings Snapshot

CRIS : 4.96 (+0.51%)
Curis Provides First Quarter 2026 Business Update

Management to host conference call today at 4:30 p.m. ET

CRIS : 4.96 (+0.51%)
Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026

LEXINGTON, Mass. , May 5, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and...

CRIS : 4.96 (+0.51%)
Curis: Q4 Earnings Snapshot

Curis: Q4 Earnings Snapshot

CRIS : 4.96 (+0.51%)
Curis Provides Fourth Quarter 2025 Business Update

Management to host conference call today at 4:30 p.m. ET

CRIS : 4.96 (+0.51%)
Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026

LEXINGTON, Mass. , March 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...

CRIS : 4.96 (+0.51%)
Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

Led by Nantahala Capital, Stonepine Capital Management, Pointillist Partners, LLC, and The Red Hook Fund, LP

CRIS : 4.96 (+0.51%)
Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

LEXINGTON, Mass. , Jan. 7, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...

CRIS : 4.96 (+0.51%)

Business Summary

Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate...

See More

Key Turning Points

3rd Resistance Point 6.04
2nd Resistance Point 5.70
1st Resistance Point 5.32
Last Price 4.96
1st Support Level 4.60
2nd Support Level 4.26
3rd Support Level 3.88

See More

52-Week High 40.28
Fibonacci 61.8% 26.28
Fibonacci 50% 21.95
Fibonacci 38.2% 17.62
Last Price 4.96
52-Week Low 3.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.